As hospital pressure stabilizes, the government unveiled the timetable for the easing of restrictive measures on Thursday January 20. Follow here all the news related to the health situation in France and around the world.
3:14 p.m.
The European Medicines Agency (EMA) has said it has approved Pfizer’s anti-Covid pill, which becomes the first antiviral medicine taken by mouth authorized in the European Union.
The EMA “has recommended authorizing Paxlovid for the treatment of Covid-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming serious,” the European regulator said in a statement. communicated.
9:12
The Israeli Ministry of Health announced on Wednesday evening to extend the injection of a 4th dose of vaccine against Covid-19 to people over 18 at risk.
Director of the Ministry of Health Nachman Ash has authorized the administration of this 4th dose for people with a higher risk of contamination, either because of illnesses or for people working in a risk environment, the ministry said. in a press release.
This decision was taken in view of the effective results of the 4th dose, administered in Israel since the beginning of the month to people over 60, the statement said.
9:10 a.m.
England on Thursday left behind almost all of the latest restrictions in place to fight Covid-19, with which the government hopes people will get used to living as they do with the flu. This wind of freedom is timely for Prime Minister Boris Johnson, more than ever weakened at the head of the government by the holiday scandal in Downing Street in defiance of anti-coronavirus rules. After ending a week ago the recommendation to work from home for those who can, England is now dropping other restrictions — among the lightest in Europe — introduced in December in the face of the wave of Omicron cases: obligation to wear a mask indoors in public places and a vaccination passport for events with a large audience.
6:12
The American company Moderna announced on Wednesday that it had started clinical trials for a booster dose of a vaccine designed specifically against the Omicron variant. These trials will include a total of 600 adults, half of whom already received two doses of Moderna’s vaccine at least six months ago, and the other half received not only those initial two doses but also at least three months ago. , the booster dose already authorized. The specific booster against Omicron will therefore be evaluated both as a third or fourth dose. The company also reported results on the effectiveness of the already authorized recall against Omicron.